New Stock News | Macau Special Administrative Region's IPO and domestic unlisted shares have been approved for full circulation by the China Securities Regulatory Commission.

On April 10, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice on the overseas issuance and listing of Shaanxi Maikote Pharmaceutical Technology Co., Ltd. and the "full circulation" of unlisted domestic shares. Maikote plans to issue no more than 66,762,400 shares of overseas listed common stock and list on the Hong Kong Stock Exchange. Twenty-four shareholders of the company plan to convert a total of 222,016,700 unlisted domestic shares into overseas listed shares and list them for trading on the Hong Kong Stock Exchange. The prospectus shows that Maikote is a biotechnology company focusing on discovering, developing, and commercializing dual/multi-specific peptide drugs for the treatment of metabolic diseases and cardiovascular diseases. The company has developed a product pipeline consisting of a core product and six other candidate products. The company's core product MT1013 is a globally innovative dual-target receptor agonist peptide drug that targets both CaSR and OGP receptors simultaneously. MT1013 is primarily developed for the treatment of SHPT and the company plans to expand its indications to include CKDMBD with osteoporosis and additional indications such as SHPT not receiving dialysis. Attachment: Shareholder names and conversion quantities for "full circulation".